FFO
CRBP icon

Fortitude Family Office’s Corbus Pharmaceuticals CRBP Stock Holding History

Fortitude Family Office’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-64
Closed -$601 – 2289
2026
Q1 		$601 Buy
+64
New +$539 ﹤0.01% 1661

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Fortitude Family Office's CRBP Position: Q2 2026 in Review

Fortitude Family Office sold out of Corbus Pharmaceuticals (CRBP) in Q2 2026, closing a stake of 64 shares — an estimated $601 sold.

Fortitude Family Office first reported a position in CRBP in Q1 2026 and held it in 1 quarter. The position peaked at $601 in Q1 2026. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Fortitude Family Office reported no remaining Corbus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Fortitude Family Office sold 64 Corbus Pharmaceuticals shares in Q2 2026, an estimated $601.
  • Fortitude Family Office first reported a position in Corbus Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Fortitude Family Office's Corbus Pharmaceuticals position peaked at $601 in Q1 2026.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.